At the Expo officially announced that Yico islets will be listed in China at the end of November 2024. It is really here!
On November 5, 2024, the seventh China International Import Expo ("Expo") opened in Shanghai, which attracted 129 from the world.3,496 companies in the country and regions participated in the exhibition, and many innovative medical technology and new drugs gathered here.The well -known host of CCTV Bai Yansong summarized the keywords of this Expo as "life" and "life". Among them, the theme of "life" is closely connected with the patients medical health, highlighting the actual needs and clinical clinical needs of patientsPain points are always the core issues that medical research and medical services are paying attention to and committed to solving.
Many cutting -edge medical products and technologies displayed at the Expo this Expo are to respond to these urgent needs of patients, and aiming to provide more accurate, efficient and convenient medical solutions.Directly hit clinical pain points.Among the many exhibits, Yi Kes insulin can effectively control the excellent performance of with only one week in injection, which has won widespread attention from the industry and served as special reports of CCTV news.So, on the international stage of the Expo, why can Icho insulin stand out and attract much attention?
Figure 1 CCTV News reporting Yico insulin
One
In response to the expectations of patients with diabetes to meet clinical needs
International Diabetes Alliance (IDF) shows that current diabetes in my country is currently in China. The number of patients has ranked first in the worlds countries.The outline of my countrys "Healthy China 2030" clearly states that diabetes management should be transformed from traditional "cure diseases" to "health -centric", advocating the formation of lifestyle, ecological environment, and social environment that is conducive to the prevention of diabetes.This change aims to effectively reduce death and disability caused by diabetes and its complications, and comprehensively improve the health level of the people [2].
Bai Yansong mentioned Yicos insulin, that is, the "Nuohe period".expect.What echo this concept is that the theme of the World Diabetes Day this year- "Diabetes and Happiness" clearly incorporates happiness into the core category of diabetes management and is closely linked to personal well -being.
Insulin therapy is an indispensable cornerstone treatment method in the treatment of diabetes. For a century, insulin preparation has adopted a variety of R & D strategies, which has undergone multiple intergenerational changes, so that the daily insulin daily agent timeGradually extend, continuously improve the efficacy, safety and compliance, but still need to be injected daily [3-5].Data show that 93%of patients using insulin and 91%of doctors said that insulin treatment is urgent to control blood sugar but do not need daily injection [6].Investigations on patients and doctors show that both doctors and patients believe that daily injection is one of the important obstacles and burdens in insulin therapy [7].Therefore, under such urgent clinical needs and patient expectations, Yico insulin as the basic insulin peripheral agent has brought new hope to diabetic patients.
Two
Innovative molecular structure design, extend the role of time
On June 18, 2024, the State Drug Administration (NMPA) officially approved the application of Yicos insulin injection in China.As the worlds first and only batch of insulin permeasians as of now, Yike insulin has changed the amino acid sequence of human insulin molecules, and is connected to the fatty acid side chain (Figure 2), so as to combine it with albumin strong and reversible to reduce it to reduce it, reduce it, and reduce it to reduce it.Slow insulin receptor-mediated removal, the role time is significantly prolonged, taking into account the efficacy and safety, and effectively improve the compliance of insulin therapy, and open the era of insulin therapy peripheral agent [8-9].
After injection of undercitin skin in Yike, combine with albumin in the blood circulation to form a repository. Subsequently, the active Icho insulin molecules are slowly and continuously released from the repository.It acts as a target organs and tissue as "trickling"; in the half-life of the human body for 196 hours, within a week of administration of administration, the effect of densely reducing the hypoglycemic effect is evenly distributed, and the time of hypoglycemic can be covered for a week [10-11]Essence
Figure 2 The molecular structure of Yi Ke insulin
Three
Global Clinical Test Verification, effective and security
Bai Yansong is aimed at the relevant person in charge of the enterprise for diabetesThe questions that patients are particularly concerned about asking: "In the past day, the basic insulin daily system, and the new preparations of the seven -day shirt now, is the same in controlling the effect of diabetes?" The person in charge said: "This is exactly the insulin of Yike is in the insulin.The established goals in the research and development process, in addition, we also consider whether the safety of the insulin can be guaranteed when the convenience is greatly improved.The efficacy and safety of Kodin in patients with type 2 diabetes have been comprehensively and rigorously verified, and 5 strict 3A clinical trials (Onwards1-5 series are random and multi-centered clinical research).Five studies cover more than 3,700 patients, which aims to evaluate the efficacy and safety of the long-term use of insulin in different patients, and compare with different basic insulin daily preparations [12-16].
Onward 1-5 Studies show that whether the patient had been treated with insulin before, the HBA1C decline in the insulin group HBA1CAmong them, onwards 1, 2, 3, and 5 have achieved excellent efficiency compared to the control group (Figure 3) [12-16].Regardless of whether the patient was previously treated with insulin therapy, the incidence of hypoglycemia in the underlying insulin daily preparation group was similar (Figure 3) [12-16].
Figure 3 Onwards1-5 Study HBA1C Decrease and Hypogencies Overview
· Summary ·
The 7th Expo ended in Shanghai on November 10th.The 6 -day exhibition has achieved fruitful results.At the Expo, Icho insulin, as the worlds first insulin perimeter to be listed, is a typical example of innovative research and development and diabetes management of "patient -centric".At the same time, taking into account the efficacy, safety and compliance, it is an important step in the direction of diabetes management towards personalized, high efficiency and humanization, and has opened a new era of diabetes management.family"35q2d0j0"> [2] https://www.gov.cn/zhengce/zhengceku/202407/Content_6965000.htm
[3] Heise T, et al. Diabetes Obes meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta meta. B. 2017 Jan; 19 (1): 3-12.
[4] Retnakan R, Zinman B. Diabetes Metab. 2022 Jan; 24 SUPPL 1: 17-26.
[5] The Diabetes Branch of the Chinese Medical Association. Chinese Diabetes Magazine. 2021; 13 (4): 315-409.
[6 6 "> 6] PEYROT M, et al. Diabetes Med. 2012; 29 (5): 682-689.
[7] chen T, et al. 2020 AUG; 42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (42 (428): 1549-1563.
[8] blair ha. BIODRugs. 2024 jul 20.
[9] Bendtsn KM, ETAl. Eur J Pharm Biopharm. 2024 AUG; 201: 114375.
[10] KJeldsen TB et al. J Med Chem. 2021; 64 (13): 8942-8950.
[11] nishimura e, et al. BMJ Open Diabetes Res Care. 2021; 9 (1) E002301.
[12] rosenstockJ, et al. N English J Med. 2023 Jul 27; 389 (4): 297-308.
[13] Philis-Tsimikas A et al. Lancet diabetes endocrinol. 2023; 11 (6): 414-425.
[14] lingval I et al. 2023 jul 18; 330 (3): 228-237.
p ID = "35q2d0jd"> [15] mathieu c et al. 2023; 401 (10392): 1929-40.[16] bajaj hs et al. Ann InternetMed. 2023 Nov; 176 (11): 1476-1485.
*"Medical Community" strives to publish the content and reliability of the content published, but not promise the accuracy of the content;Relevant parties will check or use this as a basis for decision -making.
